Integra Lifesciences Holdings (IART) Change in Accured Expenses (2009 - 2026)

Integra Lifesciences Holdings has reported Change in Accured Expenses for 18 years, with the latest figure at -$15.2 million in Q2 2026.

• Quarterly Change in Accured Expenses fell 195.45% year-over-year to -$15.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$5.6 million (down 812.09% YoY) and the FY2025 annual result came in at $26.7 million, up 1099.4% from the prior year.
• Change in Accured Expenses climbed to -$15.2 million in Q2 2026 per IART's latest filing, from -$19.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $23.0 million in Q4 2025 and troughed at -$19.2 million in Q1 2024.
• A 5-year average of -$734444.4 and a median of -$4.9 million in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses surged 1944.11% in 2022, then slumped 380.33% in 2024.
• Over 5 years, Change in Accured Expenses stood at $18.1 million in 2022, then tumbled by 89.46% to $1.9 million in 2023, then slumped by 380.33% to -$5.4 million in 2024, then jumped by 529.48% to $23.0 million in 2025, then tumbled by 166.02% to -$15.2 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$15.2 million, -$19.2 million, and $23.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.